Media
Hua Medicine to Present Additional Clinical Results at ADA 2022
May 31, 2022, Shanghai, China
Hua Medicine (the "Company", SEHK stock code: 2552.HK) today announced that it will present several clinical results on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions.
At the sessions, two research findings on dorzagliatin will be given in the form of ePoster: Firstly, a post-hoc analysis of the Phase III trials of dorzagliatin led by the former President of the Chinese Diabetes Society and present Vice President of the Asian Association for Study of Diabetes, Professor Yang Wenying of China-Japan Friendship Hospital to explore the potential of dorzagliatin in improving early phase insulin secretion and restoring glucose sensitivity in type 2 diabetes (T2D) patients. Secondly, the results of the DREAM study initiated by researchers in the dorzagliatin monotherapy (SEED) study to explore the potential of dorzagliatin in diabetes remission.
An oral presentation will also be given to publish the findings of a clinical study entitled SENSITIZE. The study, initiated by Professor Juliana Chan, an international endocrinologist from the Chinese University of Hong Kong as the researcher, explores the effects of dorzagliatin on insulin secretion and ß-cell glucose sensitivity in patients with recent onset T2D and glucokinase-maturity-onset diabetes of the young (GCK-MODY).
The ADA Annual Scientific Sessions is the largest and most important diabetes conference in the world. Every year, over ten thousand researchers and participants from around the world are attracted to report and exchange the significant progress in current diabetes research and treatment. Since 2014, Hua Medicine and its clinical experts have been presenting innovative and groundbreaking basic and clinical research results on dorzagliatin at the ADA Annual Scientific Sessions each year. This year's ADA Annual Scientific Sessions will be held in New Orleans, USA, both online and offline, from June 3-7, 2022.
Contents of Hua Medicine Presentation
ePoster Presentations | |
ePoster code: | 115-LB |
ePoster Title: | Dorzagliatin Showed Sustained Remission in an Observational Study after Discontinuation of Treatment in T2D Patients Who Achieved Good Glycemic Control with Dorzagliatin Monotherapy |
ePoster on-site display time: | 5 June 12:00 - 13:00 (Central Daylight Time) |
ePoster Location: | Hall D-E |
Theme Area: | Clinical Therapeutics/New Technology—Other Therapeutic Agents |
ePoster Presentations | |
ePoster code: | 117-LB |
ePoster Title: | Glucokinase Activator Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM Patients: A Post-hoc Analysis of the Phase III Trials of Dorzagliatin |
ePoster on-site display time: | 5 June 12:00 - 13:00 (Central Daylight Time) |
ePoster Location: | Hall D-E |
Theme Area: | Clinical Therapeutics/New Technology—Other Therapeutic Agents |
Oral Presentation | |
Report code: | 261-OR |
Report Topic: | Dorzagliatin, a Dual-Acting Glucokinase Activator. Improves Insulin Secretion and Glucose Sensitivity in Glucokinase-Maturity-Onset Diabetes of the Young (GCK-MODY) |
Report Date & Time: | 6 June 9:30 – 9:45 (Central Daylight Time) |
Reporter： | Professor Elaine Chow, The Chinese University of Hong Kong |
Theme Area: | Other Therapeutic Agents |
About Dorzagliatin
Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive and degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 diabetes. By fixing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired insulin and GLP-1 secretion of patients with Type 2 diabetes and serve as a cornerstone therapy targeting the root cause of the disease. Two Phase III registered trials for dorzagliatin monotherapy and the combination of dorzagliatin and metformin respectively have been completed in China, as well as the studies on drug mechanism synergy with sitagliptin (DPP-4 inhibitor) and empagliflozin (SGLT-2 inhibitor). In an investigator-initiated study named as DREAM, a 65.2% diabetes remission rate was observed without any antidiabetes medication during the 52-week study period. The Company has obtained the "Drug Manufacturing Permit" of dorzagliatin issued by the Shanghai Medical Products Administration, and has submitted its NDA to the National Medical Products Administration in order to realize the "First in Global, Start from China" mission for the benefits of diabetic patients worldwide.
About Hua Medicine
Hua Medicine is an innovative drug development company in China focused on developing novel therapies for patients worldwide with unmet medical needs. Hua Medicine teams up with global high caliber people and integrates global resources to explore breakthrough technologies and products and accelerate global innovation in diabetes care. Targeting the glucose sensor glucokinase, dorzagliatin, a novel oral diabetes drug restoring glucose sensitivity in T2D patients, has completed SEED and DAWN registration trials, and filed NDA in China. This global first-in-class glucokinase activator (GKA) has demonstrated its potential of achieving diabetes remission to help millions of diabetic patients around the world.
For more information
Hua Medicine
Website: www.hbyjxl.com
Investors
Email: ir@hbyjxl.com
Media
Email: pr@hbyjxl.com
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
